Format
Sort by

Send to:

Choose Destination

Search results

Items: 3

1.

Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.

Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, Zhang JR, McGrath MS, Ludington E, Appel SH, Azhir A; Phase 2 Trial NP001 Investigators.

Neurol Neuroimmunol Neuroinflamm. 2015 Apr 9;2(3):e100. doi: 10.1212/NXI.0000000000000100. eCollection 2015 Jun.

2.

Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.

Wills AM, Hubbard J, Macklin EA, Glass J, Tandan R, Simpson EP, Brooks B, Gelinas D, Mitsumoto H, Mozaffar T, Hanes GP, Ladha SS, Heiman-Patterson T, Katz J, Lou JS, Mahoney K, Grasso D, Lawson R, Yu H, Cudkowicz M; MDA Clinical Research Network.

Lancet. 2014 Jun 14;383(9934):2065-72. doi: 10.1016/S0140-6736(14)60222-1. Epub 2014 Feb 28.

3.

Recruitment strategies and comparison of prostate cancer-specific clinical data on African-American and Caucasian males with and without family history.

Mandal DM, Sartor O, Halton SL, Mercante DE, Bailey-Wilson JE, Rayford W.

Prostate Cancer Prostatic Dis. 2008;11(3):274-9. doi: 10.1038/pcan.2008.5. Epub 2008 Feb 12.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk